A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy

Inclusion Criteria: * Male or female subjects greater than or equal to 18 years. Female subjects must be of non-child bearing potential. * Clinical diagnosis of type 2 diabetes together with stages 3a, 3b or 4 CKD, based on an eGFR of 25-59 mL/min/1.73m2. * Evidence of persistent, overt albuminuria; defined as a UACR greater than or equal to 300 mg/g (greater than or equal to 33.9 mg/mmol) for greater than 3 months. Exclusion Criteria: * Subjects with CKD resulting from type 1 diabetes or non-diabetic CKD. * Subjects with poorly controlled diabetes mellitus, defined as HbA1C \>9%. * Subjects on combination ACE inhibitor/ARB therapy.